Perrigo (PRGO) Cash from Financing Activities (2013 - 2026)
Perrigo (PRGO) posted quarterly Cash from Financing Activities of -$45.3 million for Q1 2026, up 26.7% year-over-year from -$35.8 million in Q1 2025, and up 16.73% quarter-over-quarter from -$54.4 million in Q4 2025.
Perrigo (PRGO) Cash from Financing Activities (2013 - 2026) Analysis & Trends
Perrigo (PRGO) has reported Cash from Financing Activities for 14 consecutive years, with -$45.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 26.7% year-over-year to -$45.3 million; the TTM figure through Mar 2026 stood at -$204.0 million (up 66.69% YoY), while the FY2025 annual figure was -$220.5 million, up 63.91% from the prior year.
- Cash from Financing Activities advanced to -$45.3 million in Q1 2026 per PRGO's latest filing, from -$54.4 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $653.3 million in Q3 2024 and bottomed at -$1.2 billion in Q4 2024.
- Historically, Cash from Financing Activities has averaged -$37.8 million across 5 years, with a median of -$49.8 million in 2024.
- On a YoY basis, Cash from Financing Activities climbed as much as 1608.78% in 2024 and fell as far as 2487.67% in 2024.
- Perrigo's Cash from Financing Activities stood at -$42.5 million in 2022, then decreased by 4.94% to -$44.6 million in 2023, then plunged by 2487.67% to -$1.2 billion in 2024, then soared by 95.29% to -$54.4 million in 2025, then rose by 16.73% to -$45.3 million in 2026.
- Business Quant data shows PRGO's Cash from Financing Activities at -$45.3 million in Q1 2026, -$54.4 million in Q4 2025, and -$50.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -1.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -813.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -1.13 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 122.40 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -1.24 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 63.40 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | -74.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Perrigo | 1.91 Bn | 1.51 Bn | 313.90 Mn | -388.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 27, 2026 | -388.90 Mn |
| Jun 27, 2026 | -388.90 Mn |
| Mar 28, 2026 | -45.30 Mn |
| Mar 28, 2026 | -45.30 Mn |
| Dec 31, 2025 | -54.40 Mn |
| Dec 31, 2025 | -54.40 Mn |
| Sep 27, 2025 | -50.30 Mn |
| Sep 27, 2025 | -50.30 Mn |
| Jun 28, 2025 | -54.00 Mn |
| Jun 28, 2025 | -54.00 Mn |
| Mar 29, 2025 | -61.80 Mn |
| Mar 29, 2025 | -61.80 Mn |
| Dec 31, 2024 | -1.15 Bn |
| Dec 31, 2024 | -1.15 Bn |
| Sep 28, 2024 | 653.30 Mn |
| Sep 28, 2024 | 653.30 Mn |
| Jun 29, 2024 | -49.80 Mn |
| Jun 29, 2024 | -49.80 Mn |
| Mar 30, 2024 | -60.40 Mn |
| Mar 30, 2024 | -60.40 Mn |